S-8 1 brhc10022952_s8.htm S-8
As filed with the Securities and Exchange Commission on April 12, 2021
Registration No. 333-

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933


Immunocore Holdings plc
(Exact name of registrant as specified in its charter)



England and Wales
 
Not applicable
(State or other jurisdiction of Incorporation or organization)
 
(I.R.S. Employer Identification No.)
92 Park Drive
Milton Park
Abingdon, Oxfordshire OX14 4RY
United Kingdom
 (Address of principal executive offices) (Zip code)


Immunocore Limited 2020 Company Share Option Plan
Immunocore Limited 2020 Non Tax-Advantaged Share Option Plan
Immunocore Limited 2018 Non Tax-Advantaged Share Option Plan
Immunocore Limited 2015 Company Share Option Plan
Immunocore Limited 2015 Non Tax-Advantaged Share Option Plan
Immunocore Limited 2008 Share Option Scheme
Immunocore Limited Stand-Alone Equity Agreements for Ordinary Shares
Immunocore Holdings plc Stand-Alone Equity Agreements for Ordinary Shares
Immunocore Holdings plc 2021 Equity Incentive Plan, with Non-Employee Sub-Plan

(Full titles of the plan)


Immunocore, LLC
Six Tower Bridge, Suite 500
181 Washington Street
Conshohocken, Pennsylvania 19428
United States
 
Tel: +1 484 534 5261
(Name and address of agent for service) (Telephone number, including area code, of agent for service)


Copies to:

Divakar Gupta
Eric W. Blanchard
Courtney T. Thorne
Cooley LLP
55 Hudson Yards
New York, New York 10001
+1 212 479 6000
Lily Hepworth
General Counsel
Immunocore Holdings plc
92 Park Drive
Milton Park
Abingdon, Oxfordshire OX14 4RY
United Kingdom
Tel: +44 12 3543 8600
Claire Keast-Butler
Cooley (UK) LLP
Dashwood
69 Old Broad Street
London EC2M 1QS
United Kingdom
+44 20 7583 4055
 
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.

Large accelerated filer
   
Accelerated filer
 
Non-accelerated filer
 
☒ (Do not check if a smaller reporting company)
 
Smaller reporting company
 
Emerging growth company
 
       
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒


CALCULATION OF REGISTRATION FEE

Title of Securities
to be Registered(1)
Amount
to be
Registered(2)
 
Proposed
Maximum
Offering Price
Per Share
 
Proposed
Maximum
Aggregate
Offering Price
 
Amount of
Registration Fee
 
Ordinary shares, nominal value £0.002 per share
                
— Outstanding under the Registrant’s 2020 Company Share Option Plan
63,775 shares (3)
 
$17.46(4) 
 
$1,113,511.50
 
$121
 
— Outstanding under the Registrant’s 2020 Non Tax-Advantaged Share Option Plan
996,810 shares (5)
 
$17.46(6) 
 
$17,404,302.60
 
$1,899
 
— Outstanding under the Registrant’s 2018 Non Tax-Advantaged Share Option Plan
2,911,260 shares (7)
 
$17.46(8) 
 
$50,830,599.60
 
$5,546
 
— Outstanding under the Registrant’s 2015 Company Share Option Plan
99,190 shares (9)
 
$21.12(10) 
 
$2,094,892.80
 
$229
 
— Outstanding under the Registrant’s 2015 Non Tax-Advantaged Share Option Plan
117,270 shares (11)
 
$14.82(12) 
 
$1,737,941.40
 
$190
 
— Outstanding under the Immunocore Limited 2008 Share Option Scheme
266,650 shares (13)
 
$12.56(14) 
 
$3,349,124.00
 
$365
 
— Ordinary shares reserved for issuance pursuant to the Registrant’s Immunocore Limited Stand-Alone Equity Agreements for Ordinary Shares (the “Pre-IPO Awards)
68,075 shares (15)
 
$17.14(16) 
 
$1,166,805.50
 
$127
 
— Ordinary shares reserved for issuance pursuant to the Registrant’s Stand-Alone Equity Agreements for Ordinary Shares (the “IPO Awards)
174,233 shares (17)
 
$39.28(18) 
 
$6,843,872.24
 
$747
 
— Outstanding under the Registrant’s 2021 Equity Incentive Plan (Options), with non-Employee Sub-Plan
4,618,762 shares (19)
 
$26.36(20) 
 
$121,750,566.32
 
$13,282
 
— Ordinary shares reserved for future grant under the Registrant’s 2021 Equity Incentive Plan, with Non-Employee Sub-Plan
1,482,428 shares (21)
 
$40.24(22) 
 
$59,652,902.72
 
$6,508
 
Total
10,798,453 shares
      
$265,944,518.68
 
$29,014
 


(1)
These ordinary shares, nominal value £0.002 per share (“Ordinary Shares) may be represented by the American Depositary Shares (ADSs) of Immunocore Holdings plc (the Registrant), each of which represents one Ordinary Share. The Registrants ADSs issuable upon deposit of the Ordinary Shares registered hereby have been registered under a separate registration statement on Form F-6 (File No. 333-252487).
(2)
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the Securities Act), this Registration Statement shall also cover any additional Ordinary Shares of the Registrant that become issuable under the above-named plans by reason of any stock dividend, stock split, recapitalization or other similar transaction.
(3)
Represents Ordinary Shares issuable upon the exercise of outstanding stock option awards under the 2020 Company Share Option Plan(the “2020 CSOP”) as of March 25, 2021. No further grants will be made under the 2020 CSOP. To the extent outstanding options granted under the 2020 CSOP are cancelled, forfeited or otherwise terminated without being exercised and would otherwise have been returned to the share reserve under the 2020 CSOP, the number of shares underlying such awards will be available for future grant under the 2021 Equity Incentive Plan (the “2021 Plan”). See footnote 21 below.
(4)
Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(h) of the Securities Act, and based on $17.46 per share, the weighted average exercise price (rounded to the nearest cent) of the outstanding option awards under the 2020 CSOP as of March 25, 2021.
(5)
Represents Ordinary Shares issuable upon the exercise of outstanding stock option awards under the 2020 Non Tax-Advantaged Share Option Plan (the “2020 SOP”) as of March 25, 2021. No further grants will be made under the 2020 SOP. To the extent outstanding options granted under the 2020 SOP are cancelled, forfeited or otherwise terminated without being exercised and would otherwise have been returned to the share reserve under the 2020 SOP, the number of shares underlying such awards will be available for future grant under the 2021 Plan. See footnote 19 below.
(6)
Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(h) of the Securities Act, and based on $17.46 per share, the weighted average exercise price (rounded to the nearest cent) of the outstanding option awards under the 2020 SOP as of March 25, 2021.
(7)
Represents Ordinary Shares issuable upon the exercise of outstanding stock option awards under the 2018 Non Tax-Advantaged Share Option Plan (the “2018 SOP”) as of March 25, 2021. No further grants will be made under the 2018 SOP. To the extent outstanding options granted under the 2018 SOP are cancelled, forfeited or otherwise terminated without being exercised and would otherwise have been returned to the share reserve under the 2018 SOP, the number of shares underlying such awards will be available for future grant under the 2021 Plan. See footnote 19 below.


(8)
Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(h) of the Securities Act, and based on $17.46 per share, the weighted average exercise price (rounded to the nearest cent) of the outstanding option awards under the 2018 SOP as of March 25, 2021.
(9)
Represents Ordinary Shares issuable upon the exercise of outstanding stock option awards under the 2015 Company Share Option Plan (the “2015 CSOP”) as of March 25, 2021. No further grants will be made under the 2015 CSOP. To the extent outstanding options granted under the 2015 CSOP are cancelled, forfeited or otherwise terminated without being exercised and would otherwise have been returned to the share reserve under the 2015 CSOP, the number of shares underlying such awards will be available for future grant under the 2021 Plan. See footnote 19 below.
(10)
Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(h) of the Securities Act, and based on $21.12 per share, the weighted average exercise price (rounded to the nearest cent) of the outstanding option awards under the 2015 CSOP as of March 25, 2021.
(11)
Represents Ordinary Shares issuable upon the exercise of outstanding stock option awards under the 2015 Non Tax-Advantaged Share Option Plan (the “2015 SOP”) as of March 25, 2021. No further grants will be made under the 2015 SOP. To the extent outstanding options granted under the 2015 SOP are cancelled, forfeited or otherwise terminated without being exercised and would otherwise have been returned to the share reserve under the 2015 SOP, the number of shares underlying such awards will be available for future grant under the 2021 Plan. See footnote 19 below.
(12)
Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(h) of the Securities Act, and based on $14.82 per share, the weighted average exercise price (rounded to the nearest cent) of the outstanding option awards under the 2015 SOP as of March 25, 2021.
(13)
Represents Ordinary Shares issuable upon the exercise of outstanding stock option awards under the Immunocore Limited 2008 Share Option Scheme (the “2008 SOP”) as of March 25, 2021. No further grants will be made under the 2008 SOP. To the extent outstanding options granted under the 2008 SOP are cancelled, forfeited or otherwise terminated without being exercised and would otherwise have been returned to the share reserve under the 2008 SOP, the number of shares underlying such awards will be available for future grant under the 2021 Plan. See footnote 19 below.
(14)
Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(h) of the Securities Act, and based on $12.56 per share, the weighted average exercise price (rounded to the nearest cent) of the outstanding option awards under the 2008 SOP as of March 25, 2021.
(15)
Consists of the Registrant’s Ordinary Shares underlying the Pre-IPO Awards to persons not participating in the above mentioned plans.
(16)
Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(h) of the Securities Act, and based on $17.14 per share, the weighted average exercise price (rounded to the nearest cent) of the Pre-IPO Awards as of March 25, 2021. No further grants will be made pursuant to the Pre-IPO Awards. To the extent outstanding Pre-IPO Awards are cancelled, forfeited or otherwise terminated without being exercised, the number of shares underlying such awards will be available for future grant under the 2021 Plan. See footnote 19 below.
(17)
Consists of the Registrant’s Ordinary Shares underlying the IPO Awards which were issued to former service providers of the Company.
(18)
Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(h) of the Securities Act, and based on $39.28 per share, the weighted average exercise price (rounded to the nearest cent) of the IPO Awards as of March 25, 2021.
(19)
Represents Ordinary Shares reserved for issuance upon the exercise of outstanding options granted under the 2021 Plan.
(20)
Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(h) of the Securities Act, and based on $26.36 per share, the weighted average exercise price (rounded to the nearest cent) for outstanding options granted under the 2021 Plan.
(21)
Represents Ordinary Shares reserved for future issuance pursuant to awards under the 2021 Plan. The 2021 Plan also provides that the number of shares of Common Stock reserved for issuance under the 2021 Plan will automatically increase on January 1st of each year, commencing on January 1, 2022 and ending on (and including) January 1, 2031, in an amount equal to 5% of the total number of Ordinary Shares outstanding on December 31 of the preceding calendar year. The Registrant’s board may act prior to January 1 of a given year to provide that there will be no increase for such year or that the increase for such year will be a lesser (but not greater) number of Ordinary Shares. This explanation is provided for information purposes only. The issuance of such shares is not being registered on this Registration Statement.
(22)
Estimated in accordance with Rule 457(c) of the Securities Act solely for purposes of calculating the registration fee, and is based upon $40.24, which was the average of the high and low prices of the Registrants ADSs as reported on the Nasdaq Global Select Market on April 6, 2021.


PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
 
The information specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement in accordance with the provisions of Rule 428 under the Securities Act. The documents containing the information specified in Item 1 and Item 2 of Part I of Form S-8 will be delivered to the participants in the plan covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act.
 
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
 
Item 3.
Incorporation of Documents By Reference.
 
The following documents, which have been filed with the U.S. Securities and Exchange Commission (the Commission) by Immunocore Holdings plc (the Registrant) are hereby incorporated by reference into this Registration Statement:
 
(a) the Registrants Annual Report on Form 20-F filed with the Commission on March 25, 2021;
 
(b) all other reports filed by the Registrant pursuant to Sections 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the annual report referred to in (a) above; and
 
(c) the descriptions of the Registrants American Depositary Shares and Ordinary Shares contained in the Registrants Registration Statement on Form 8-A filed on February 2, 2021 (File No. 001-39992) under the Securities Exchange Act of 1934, as amended (the Exchange Act), including any amendment or report filed for the purpose of updating such description.
 
All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act subsequent to the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all such securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part hereof from the date of filing of such documents.
 
Any statement contained in this Registration Statement, in an amendment hereto or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed amendment to this Registration Statement or in any document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement, except as to specific section of such statements as set forth therein.
 
Under no circumstances shall any information furnished on Form 6-K be deemed incorporated herein by reference unless such Form 6-K expressly provides to the contrary.
 
Item 4.
Description of Securities.
 
Not applicable.
 
Item 5.
Interests of Named Experts and Counsel.
 
Not applicable.


Item 6.
Indemnification of Directors and Officers.
 
Subject to the U.K. Companies Act 2006, members of the Registrants board of directors and its officers have the benefit of the following indemnification provisions in the Registrants Articles of Association:
 
Current and former members of the Registrants board of directors or officers shall be reimbursed for:
 
(i) all costs, charges, losses, expenses and liabilities sustained or incurred in relation to his or her actual or purported execution of his or her duties in relation to the Registrant, including any liability incurred in defending any criminal or civil proceedings; and
 
(ii) expenses incurred or to be incurred in defending any criminal or civil proceedings, in an investigation by a regulatory authority or against a proposed action to be taken by a regulatory authority, or in connection with any application for relief under the statutes of the United Kingdom and any other statutes that concern and affect the Registrant as a company (collectively, the Statutes) arising in relation to the Registrant or an associated company, by virtue of the actual or purposed execution of the duties of his or her office or the exercise of his or her powers.
 
In the case of current or former members of the Registrants board of directors, there shall be no entitlement to reimbursement as referred to above for (i) any liability incurred to the Registrant or any associated company, (ii) the payment of a fine imposed in any criminal proceeding or a penalty imposed by a regulatory authority for non-compliance with any requirement of a regulatory nature, (iii) the defense of any criminal proceeding if the member of the Registrants board of directors is convicted, (iv) the defense of any civil proceeding brought by the Registrant or an associated company in which judgment is given against the director, and (v) any application for relief under the statutes of the United Kingdom and any other statutes that concern and affect the Registrant as a company in which the court refuses to grant relief to the director.
 
In addition, members of the Registrants board of directors and its officers who have received payment from the Registrant under these indemnification provisions must repay the amount they received in accordance with the Statutes or in any other circumstances that the Registrant may prescribe or where the Registrant has reserved the right to require repayment.
 
In addition, the Registrant has entered or intends to enter into a deed of indemnity with each of its directors and officers. In addition to such indemnification, the Registrant provides its directors and officers with directors and officers liability insurance.
 
Item 7.
Exemption From Registration Claimed.
 
Not applicable.


Item 8.
Exhibits.

       
Incorporated by Reference
Exhibit
Number
 
Description
 
Schedule
Form
 
File Number
 
Exhibit
 
Filing Date
           
4.1
   
20-F
 
001-39992
 
1.1
 
3/25/21
           
4.2
   
20-F
 
001-39992
 
2.2
 
3/25/21
           
4.3
   
20-F
 
001-39992
 
2.3
 
3/25/21
           
 
Opinion of Cooley (UK) LLP.
               
           
 
Consent of KPMG LLP, the Registrant’s independent registered public accounting firm
               
           
 
Consent of Cooley (UK) LLP (included in Exhibit 5.1).
               
           
 
Power of Attorney (included on the signature page of this Registration Statement)
               
           
 
Immunocore Limited 2020 Company Share Option Plan
               
                     
 
Immunocore Limited 2020 Non Tax-Advantaged Share Option Plan.
               
                     
 
Immunocore Limited 2018 Non Tax-Advantaged Share Option Plan.
               
                     
 
Immunocore Limited 2015 Share Option Plan.
               
                     
 
Immunocore Limited 2015 Non Tax-Advantaged Share Option Plan.
               
                     
 
Immunocore Limited 2008 Share Option Scheme.
               
   
               
 
Immunocore Limited Form of Stand-Alone Equity Agreement for Ordinary Shares.
               
                     
 
Immunocore Holdings Limited Form of Stand-Alone Equity Agreement for Ordinary Shares.
               
                     
99.9
   
20-F
 
001-39992
 
4.20
 
3/25/21


*
Filed herewith.


Item 9.
Undertakings.
 
(a) The undersigned Registrant hereby undertakes:
 
(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
 
(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;
 
(ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the Calculation of Registration Fee table in the effective Registration Statement; and
 
(iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;
 
provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.
 
(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; and
 
(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
 
(b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrants annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plans annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
 
(h) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.


SIGNATURES
 
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Oxford, United Kingdom, on the 12th day of April, 2021.

 
IMMUNOCORE HOLDINGS PLC
     
 
By:
/s/ Bahija Jallal, Ph.D.
   
Bahija Jallal, Ph.D.
   
Chief Executive Officer


POWER OF ATTORNEY
 
KNOW ALL BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Bahija Jallal and Brian Di Donato, and each or any one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.
 
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

Signature
 
Title
 
Date
         
/s/ Bahija Jallal, Ph.D.
 
Chief Executive Officer and Director
(Principal Executive Officer)
 
April 12, 2021
Bahija Jallal, Ph.D.
 
         
/s/ Brian Di Donato
 
Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)
 
April 12, 2021
Brian Di Donato
 
         
/s/ Professor Sir John Bell
 
Chairman of the Board of Directors
 
April 12, 2021
Professor Sir John Bell
 
         
/s/ Travis Coy
 
Director
 
April 12, 2021
Travis Coy
 
         
/s/ Roy Herbst, M.D., Ph.D.
 
Director
 
April 12, 2021
Roy Herbst, M.D., Ph.D.
 
/s/ Robert Perez
 
Director
 
April 12, 2021
Robert Perez
 
         
/s/ Kristine Peterson
 
Director
 
April 12, 2021
Kristine Peterson
 
         
/s/ Professor Sir Peter Ratcliffe
 
Director
 
April 12, 2021
Professor Sir Peter Ratcliffe
 


Immunocore, LLC
 
April 12, 2021
     
By:
/s/ Bahija Jallal, Ph.D.
Authorized Representative in the United States
 
       
 
Name: Bahija Jallal, Ph.D.
   
 
Title: Authorized Signatory